Cargando…
Clinical anticancer drug development: targeting the cyclin-dependent kinases
Cell division involves a cyclical biochemical process composed of several step-wise reactions that have to occur once per cell cycle. Dysregulation of cell division is a hallmark of all cancers. Genetic and epigenetic mechanisms frequently result in deranged expression and/or activity of cell-cycle...
Autores principales: | Benson, C, Kaye, S, Workman, P, Garrett, M, Walton, M, de Bono, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361734/ https://www.ncbi.nlm.nih.gov/pubmed/15558073 http://dx.doi.org/10.1038/sj.bjc.6602229 |
Ejemplares similares
-
Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs
por: Cummings, J, et al.
Publicado: (2010) -
A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days
por: Benson, C, et al.
Publicado: (2007) -
Toxicity of targeted anticancer treatments on the liver in myeloproliferative neoplasms
por: Purwar, Shubhrat, et al.
Publicado: (2023) -
The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug
por: Sacco, Francesca, et al.
Publicado: (2016) -
DNA G-quadruplex-stabilizing metal complexes as anticancer drugs
por: Zegers, Jaccoline, et al.
Publicado: (2022)